{"id":"intrathecal-injection-of-pemetrexed","safety":{"commonSideEffects":[{"rate":null,"effect":"Neurotoxicity"},{"rate":null,"effect":"Myelosuppression"},{"rate":null,"effect":"Chemical arachnoiditis"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fever"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Pemetrexed is a multitargeted antifolate that inhibits thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase, blocking purine and pyrimidine synthesis. When administered intrathecally, it achieves high local concentrations in the central nervous system to treat leptomeningeal malignancies while minimizing systemic exposure.","oneSentence":"Pemetrexed inhibits multiple folate-dependent enzymes involved in nucleotide synthesis, disrupting DNA and RNA production in cancer cells when delivered directly into the cerebrospinal fluid.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:49:44.750Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Leptomeningeal metastases (carcinomatous meningitis)"},{"name":"CNS lymphoma"}]},"trialDetails":[{"nctId":"NCT06663306","phase":"PHASE1","title":"Intrathecal Injection Pemetrexed And Bevacizumab in Patients With Leptomeningeal Metastases in NSCLC","status":"RECRUITING","sponsor":"Shanghai Chest Hospital","startDate":"2024-12-09","conditions":"Lung Cancer (NSCLC), Leptomeningeal Metastasis","enrollment":19},{"nctId":"NCT06230055","phase":"PHASE4","title":"Intrathecal Chemotherapy Through Ommaya Reservoir Upon Her-2 Negative Breast Cancer With Leptomeningeal Metastasis","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-01-05","conditions":"HER2-negative Breast Cancer, Leptomeningeal Metastasis","enrollment":37},{"nctId":"NCT07092202","phase":"PHASE4","title":"Firmonertinib Combined With Intrathecal Injection for the Treatment of EGFR Mutant NSCLC With Leptomeningeal Metastases","status":"RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2025-04-15","conditions":"Leptomeningeal Metastasis, NSCLC, Intrathecal Chemotherapy","enrollment":40},{"nctId":"NCT06762080","phase":"PHASE1, PHASE2","title":"Intrathecal Combination of Programmed Death-1 (PD-1)/Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Bispecific Antibody and Pemetrexed for Leptomeningeal Metastasis","status":"RECRUITING","sponsor":"Guangzhou Medical University","startDate":"2025-03-07","conditions":"Leptomeningeal Metastasis","enrollment":36},{"nctId":"NCT06809517","phase":"PHASE1, PHASE2","title":"Intrathecal PD-1/VEGF Bispecific Antibody Plus Pemetrexed for Leptomeningeal Metastasis","status":"RECRUITING","sponsor":"Guangzhou Medical University","startDate":"2025-03-18","conditions":"Leptomeningeal Metastasis, Intrathecal Drug Delivery","enrollment":34},{"nctId":"NCT06809530","phase":"PHASE1, PHASE2","title":"Intrathecal Dual Checkpoint Inhibitor (PD-1 and CTLA-4) in Combination With Pemetrexed for Leptomeningeal Metastasis","status":"RECRUITING","sponsor":"Guangzhou Medical University","startDate":"2025-03-17","conditions":"Leptomeningeal Metastasis, Pemetrexed, PD-1 Inhibitor","enrollment":34},{"nctId":"NCT05289908","phase":"PHASE1, PHASE2","title":"Intrathecal Pemetrexed for Leptomeningeal Metastasis","status":"COMPLETED","sponsor":"The First Hospital of Jilin University","startDate":"2022-02-21","conditions":"Leptomeningeal Metastases","enrollment":34},{"nctId":"NCT06861218","phase":"PHASE2","title":"Cerebrospinal Fluid Cytology-guided Intrathecal Chemo-holiday Therapy for EGFR-positive NSCLC Leptomeningeal Metastases","status":"NOT_YET_RECRUITING","sponsor":"Zhejiang Cancer Hospital","startDate":"2025-04","conditions":"Leptomeningeal Metastases","enrollment":42},{"nctId":"NCT06812871","phase":"PHASE2","title":"High-dose Furmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed Chemotherapy in Patients With EGFR-mutated Non-small Cell Lung Cancer and Meningeal Metastasis","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-11-01","conditions":"Non-small Cell Lung Cancer Metastatic","enrollment":30},{"nctId":"NCT06431685","phase":"PHASE1","title":"Safety and Efficacy of Whole Brain LDRT+ICI+Intrathecal Chemotherapy in Refractory Meningeal Metastasis of Lung Cancer","status":"RECRUITING","sponsor":"Sichuan University","startDate":"2024-04-25","conditions":"NSCLC, Low Dose Radiotherapy, PD-1 Inhibitor","enrollment":10},{"nctId":"NCT06346977","phase":"","title":"Diagnosis of Leptomeningeal Metastasis and the Monitoring of Intrathecal Chemotherapy Efficacy in NSCLC","status":"NOT_YET_RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2024-04-01","conditions":"Diagnosis","enrollment":60},{"nctId":"NCT06132698","phase":"PHASE2","title":"Immune Checkpoint Inhibitors Intrathecal Injection in Patients With Leptomeningeal Metastases in NSCLC","status":"UNKNOWN","sponsor":"West China Hospital","startDate":"2023-11-30","conditions":"NSCLC Associated With Leptomeningeal Metastases","enrollment":17},{"nctId":"NCT05459441","phase":"EARLY_PHASE1","title":"Efficacy and Safety Evaluation of Percutaneous Ommaya Capsule Injection of Autologous Bi-dimensional Specific T Cells in the Treatment of Glioma and in Combination With Pemetrexed in the Treatment of Brain/Meningeal Metastases","status":"UNKNOWN","sponsor":"Shanghai Pudong Hospital","startDate":"2022-01-01","conditions":"Glioma, Brain Metastases","enrollment":30},{"nctId":"NCT03507244","phase":"PHASE1, PHASE2","title":"Concurrent Intrathecal-pemetrexed and Involved-field Radiotherapy for Leptomeningeal Metastasis From Solid Tumors","status":"COMPLETED","sponsor":"The First Hospital of Jilin University","startDate":"2018-04-12","conditions":"Leptomeningeal Metastasis","enrollment":34},{"nctId":"NCT03101579","phase":"PHASE1","title":"Intrathecal Pemetrexed for Recurrent Leptomeningeal Metastases From Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"The First Hospital of Jilin University","startDate":"2017-03-01","conditions":"Leptomeningeal Metastases","enrollment":13}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Intrathecal injection of pemetrexed","genericName":"Intrathecal injection of pemetrexed","companyName":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","companyId":"union-hospital-tongji-medical-college-huazhong-university-of-science-and-technol","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Pemetrexed inhibits multiple folate-dependent enzymes involved in nucleotide synthesis, disrupting DNA and RNA production in cancer cells when delivered directly into the cerebrospinal fluid. Used for Leptomeningeal metastases (carcinomatous meningitis), CNS lymphoma.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}